Expert: Professor Jorge Cortes Georgia Cancer Centre, Augusta (USA)

Program:
Overview of significant clinical aspects presented during the meeting, including:

• 01:37 Update on new drugs under development
  • Asciminib update - Efficacy and safety results ASCEMBL study
  • Ponatinib update - Post-hoc analysis OPTIC trial
  • Vodobatinib update - Efficacy results
• 06:44 Real-world data
  
  • Clinical trials vs real-world data
  • Real-world experience with Asciminib
• 08:23 Impact of gene variant SLA1 as a predictor of treatment response/progression
• 09:36 Various aspects around the concept of treatment-free remission
• 11:54 Patient-reported outcomes
• 12:20 Michele Baccarani Special Symposium
• 15:58 Debate: What is most important for CML persistence of the disease? Extrinsic factors or intrinsic factors?
• 16:48 Debate: Is Ponatinib still the drug of choice for 3rd line therapy?

19:30 Q&A Session

If you have any questions or comments to the speaker, please email info@cml-foundation.org.